Gyre Therapeutics Inc GYRE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/24/24 EDT
11.99UNCH (UNCH)
Volume
573
Close
11.99quote price arrow down-0.62 (-4.92%)
Volume
108,866
52 week range
3.15 - 30.40
Loading...
  • Open12.45
  • Day High12.61
  • Day Low10.91
  • Prev Close12.61
  • 52 Week High30.40
  • 52 Week High Date12/21/23
  • 52 Week Low3.15
  • 52 Week Low Date06/01/23

Key Stats

  • Market Cap1.025B
  • Shares Out85.51M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta2.02
  • YTD % Change-53.33

KEY STATS

  • Open12.45
  • Day High12.61
  • Day Low10.91
  • Prev Close12.61
  • 52 Week High30.40
  • 52 Week High Date12/21/23
  • 52 Week Low3.15
  • 52 Week Low Date06/01/23
  • Market Cap1.025B
  • Shares Out85.51M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta2.02
  • YTD % Change-53.33

RATIOS/PROFITABILITY

  • EPS (TTM)-1.92
  • P/E (TTM)-6.24
  • Fwd P/E (NTM)-19.98
  • EBITDA (TTM)33.428M
  • ROE (TTM)-558.29%
  • Revenue (TTM)140.622M
  • Gross Margin (TTM)96.01%
  • Net Margin (TTM)-53.91%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/15/2024(est)
  • Ex Div Date01/13/2023
  • Div Amount0.24
  • Split Date-
  • Split Factor-

Latest On Gyre Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Gyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in the research, development, manufacturing and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing...
Ying Luo Ph.D.
Non-Executive Chairman of the Board
Han Ying Ph.D.
Chief Executive Officer, Director
Songjiang Ma
President, Director
Weiguo Ye
Chief Operating Officer
Ruoyu Chen
Interim Chief Financial Officer
Address
12770 High Bluff Drive, Suite 150
San Diego, CA
92130
United States